Therapeutic Efficacy of a Human Papillomavirus Type 16 E7 Bacterial Exotoxin Fusion Protein Adjuvanted with CpG or GPI-0100 in a Preclinical Mouse Model for HPV-associated Disease

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2019 Apr 24

PMID 31010714

Citations 14

Authors

Diane M Da Silva

Joseph G Skeate

Elena Chavez-Juan

Kim P Luhen

Jiun-Ming Wu

Chia-Mao Wu

W Martin Kast

KinKai Hwang

Affiliations

Soon will be listed here.

Abstract

Persistent human papillomavirus (HPV) infection is causally linked to the development of several human cancers, including cervical, vulvar, vaginal, anal, penile, and oropharyngeal cancers. To address the need for a therapeutic vaccine against HPV-associated diseases, here we test and compare the immunogenicity and therapeutic efficacy of a bacterial exotoxin fusion protein covalently linked to the HPV16 E7 oncoprotein adjuvanted with CpG or GPI-0100 in the C3.43 preclinical HPV16-transformed tumor model. We show that TVGV-1 protein vaccine adjuvanted with either CpG or GPI-0100 adjuvant induces a high frequency of E7-specific CD8 T cells, and both adjuvants are able to assist the immune response in inducing polyfunctional cytokine-secreting lytic T cells that show therapeutic efficacy against well-established C3.43 tumors. CpG-adjuvanted TVGV-1 resulted in higher frequencies of IFNγ secreting and degranulating E7-specific T cells compared to GPI-0100-adjuvanted TVGV-1, resulting in marginally increased in vivo efficacy. Despite minor differences in immune response outcomes, we consider both CpG ODN and GPI-0100 to be promising vaccine adjuvants to increase the immunogenicity and therapeutic efficacy of the TVGV-1 protein for HPV16-driven cancers.

Citing Articles

Roles of human papillomavirus in cancers: oncogenic mechanisms and clinical use.

Zhang Y, Qiu K, Ren J, Zhao Y, Cheng P Signal Transduct Target Ther. 2025; 10(1):44.

PMID: 39856040 PMC: 11760352. DOI: 10.1038/s41392-024-02083-w.

A comprehensive bibliometric analysis (2000-2022) on the mapping of knowledge regarding immunotherapeutic treatments for advanced, recurrent, or metastatic cervical cancer.

Duan Y, Yang L, Wang W, Zhang P, Fu K, Li W Front Pharmacol. 2024; 15:1351363.

PMID: 38799160 PMC: 11116801. DOI: 10.3389/fphar.2024.1351363.

Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions.

Ye J, Zheng L, He Y, Qi X MedComm (2020). 2023; 4(5):e368.

PMID: 37719443 PMC: 10501338. DOI: 10.1002/mco2.368.

Immune Environment and Immunotherapy in Endometrial Carcinoma and Cervical Tumors.

Laine A, Gonzalez-Lopez A, Hasan U, Ohkuma R, Ray-Coquard I Cancers (Basel). 2023; 15(7).

PMID: 37046702 PMC: 10093320. DOI: 10.3390/cancers15072042.

Liposomal Formulations of a Polyleucine-Antigen Conjugate as Therapeutic Vaccines against Cervical Cancer.

Firdaus F, Bartlett S, Hussein W, Lu L, Wright Q, Huang W Pharmaceutics. 2023; 15(2).

PMID: 36839923 PMC: 9965676. DOI: 10.3390/pharmaceutics15020602.

References

Marciani D, Press J, Reynolds R, Pathak A, Pathak V, Gundy L . Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine. 2000; 18(27):3141-51. DOI: 10.1016/s0264-410x(00)00118-3. View

Kim S, Ragupathi G, Cappello S, Kagan E, Livingston P . Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. Vaccine. 2000; 19(4-5):530-7. DOI: 10.1016/s0264-410x(00)00195-x. View

Evans T, McElrath M, Matthews T, Montefiori D, Weinhold K, Wolff M . QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine. 2001; 19(15-16):2080-91. DOI: 10.1016/s0264-410x(00)00415-1. View

Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas Z . Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol. 2001; 31(7):2154-63. DOI: 10.1002/1521-4141(200107)31:7<2154::aid-immu2154>3.0.co;2-u. View

Bauer S, Kirschning C, Hacker H, Redecke V, Hausmann S, Akira S . Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A. 2001; 98(16):9237-42. PMC: 55404. DOI: 10.1073/pnas.161293498. View

Ragupathi G, Coltart D, Williams L, Koide F, Kagan E, Allen J . On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines. Proc Natl Acad Sci U S A. 2002; 99(21):13699-704. PMC: 129747. DOI: 10.1073/pnas.202427599. View

Marciani D, Reynolds R, Pathak A, Finley-Woodman K, May R . Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100. Vaccine. 2003; 21(25-26):3961-71. DOI: 10.1016/s0264-410x(03)00298-6. View

Zhang P, Yang Q, Marciani D, Martin M, Clements J, Michalek S . Effectiveness of the quillaja saponin semi-synthetic analog GPI-0100 in potentiating mucosal and systemic responses to recombinant HagB from Porphyromonas gingivalis. Vaccine. 2003; 21(27-30):4459-71. DOI: 10.1016/s0264-410x(03)00438-9. View

Wu J, Gardner B, Murphy C, Seals J, Kensil C, Recchia J . Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J Immunol. 1992; 148(5):1519-25. View

10.

Preville X, Ladant D, Timmerman B, Leclerc C . Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein. Cancer Res. 2005; 65(2):641-9. View

11.

Kreimer A, Clifford G, Boyle P, Franceschi S . Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005; 14(2):467-75. DOI: 10.1158/1055-9965.EPI-04-0551. View

12.

Slovin S, Ragupathi G, Fernandez C, Jefferson M, Diani M, Wilton A . A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21. Vaccine. 2005; 23(24):3114-22. DOI: 10.1016/j.vaccine.2005.01.072. View

13.

Peng S, Tomson T, Trimble C, He L, Hung C, Wu T . A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. Gene Ther. 2005; 13(3):257-65. PMC: 2174916. DOI: 10.1038/sj.gt.3302646. View

14.

Liao C, Chen C, Lee C, Su Y, Chang M, Syu M . Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects. Cancer Res. 2005; 65(19):9089-98. DOI: 10.1158/0008-5472.CAN-05-0958. View

15.

Marciani D, Kensil C, Beltz G, Hung C, Cronier J, Aubert A . Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats. Vaccine. 1991; 9(2):89-96. DOI: 10.1016/0264-410x(91)90262-5. View

16.

Kanodia S, Fahey L, Kast W . Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets. 2007; 7(1):79-89. DOI: 10.2174/156800907780006869. View

17.

Santos F, Borja-Cabrera G, Miyashiro L, Grechi J, Reis A, Moreira M . Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine. Vaccine. 2007; 25(33):6176-90. PMC: 7115527. DOI: 10.1016/j.vaccine.2007.06.005. View

18.

Huang C, Chen C, Lee C, Chang M, Su Y, Lin Y . DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens. Gynecol Oncol. 2007; 107(3):404-12. DOI: 10.1016/j.ygyno.2007.06.031. View

19.

Vandepapeliere P, Horsmans Y, Moris P, Van Mechelen M, Janssens M, Koutsoukos M . Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine. 2008; 26(10):1375-86. DOI: 10.1016/j.vaccine.2007.12.038. View

20.

Sun H, Xie Y, Ye Y . Advances in saponin-based adjuvants. Vaccine. 2009; 27(12):1787-96. DOI: 10.1016/j.vaccine.2009.01.091. View